Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05497674
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 45
- Registration Number
- NCT05431673
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05389722
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 105
- Registration Number
- NCT05388448
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-08-21
- Target Recruit Count
- 330
- Registration Number
- NCT05383742
- Locations
- 🇲🇼
Malawi CRS, Lilongwe, Malawi
🇧🇷Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, Brazil
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (12101), Rio De Janeiro, Brazil
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT05372367
- Locations
- 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇧🇪Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇪🇸Hospital Quiron. I.C.U., Barcelona, Spain
Drug-drug Interaction Study of SPH3127
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT05359055
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT05338489
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.